User:Mr. Ibrahem/Olopatadine

From Wikipedia, the free encyclopedia

Mr. Ibrahem/Olopatadine
Clinical data
Trade namesPatanol and others
AHFS/Drugs.comMonograph
MedlinePlusa602025
License data
Pregnancy
category
  • C
Routes of
administration		Eye drops, nasal spray
Drug classAntihistamine, mast cell stabilizer.[1][2]
Legal status
Legal status
Pharmacokinetic data
Elimination half-life3 hours
Identifiers
  • {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-
    dihydrodibenzo[b,e]oxepin-2-yl}acetic acid
Chemical and physical data
FormulaC21H23NO3
Molar mass337.419 g·mol−1
3D model (JSmol)
  • O=C(O)Cc2ccc1OCc3c(C(\c1c2)=C\CCN(C)C)cccc3
  • InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8- checkY
  • Key:JBIMVDZLSHOPLA-LSCVHKIXSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Olopatadine is a medication used to decrease the symptoms of allergic conjunctivitis and allergic rhinitis (hay fever).[2] It is used as eye drops or as a nasal spray.[2] The eye drops general result in an improvement within half an hour.[2]

Common side effects include headache, sore throat, eye discomfort, and change in taste.[4][2] More significant side effects may include sleepiness.[2] It is unclear if use during pregnancy or breastfeeding is safe.[6] It is an antihistamine and mast cell stabilizer.[1][2]

Olopatadine was patented in 1986 and came into medical use in 1997.[7] It is available as a generic medication.[2] A 5 milliliter bottle of the eye drops in the United Kingdom costs the NHS less than £5 as of 2019.[4] In the United States the wholesale cost of this amount is about US$12.50.[8] In 2017, it was the 270th most commonly prescribed medication in the United States, with more than one million prescriptions.[9][10]

References[edit]

  1. ^ a b Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A (June 2015). "Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis" (PDF). The Cochrane Database of Systematic Reviews. 6 (6): CD009566. doi:10.1002/14651858.CD009566.pub2. hdl:2164/6048. PMID 26028608. Archived from the original on 28 August 2021. Retrieved 24 September 2019.
  2. ^ a b c d e f g h i j "Olopatadine Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 27 March 2019. Retrieved 26 March 2019.
  3. ^ "FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process". U.S. Food and Drug Administration (FDA). 14 February 2020. Archived from the original on 15 February 2020. Retrieved 14 February 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  4. ^ a b c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1126. ISBN 9780857113382.
  5. ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 5 March 2021. Retrieved 9 September 2020.
  6. ^ "Olopatadine ophthalmic Use During Pregnancy". Drugs.com. Archived from the original on 26 March 2019. Retrieved 26 March 2019.
  7. ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 549. ISBN 9783527607495. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
  8. ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
  9. ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
  10. ^ "Olopatadine - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Olopatadine&oldid=1161309834"